Omeros Corp. buy marge
Start price
17.05.17
/
50%
€14.82
Target price
04.11.21
€30.67
Performance (%)
-58.16%
End price
05.11.21
€6.20
Summary
This prediction ended on 05.11.21 with a price of €6.20. Massive losses of -58.16% were the result for the BUY prediction by marge. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Omeros Corp. | 27.544% | 27.544% | -0.220% | -60.505% |
| iShares Core DAX® | 1.776% | 3.175% | 14.882% | 17.660% |
| iShares Nasdaq 100 | -1.037% | 1.869% | 35.463% | 52.324% |
| iShares Nikkei 225® | -0.335% | 3.857% | 14.485% | 11.459% |
| iShares S&P 500 | 0.854% | 2.567% | 31.105% | 47.441% |
Comments by marge for this prediction
In the thread Omeros Corp. diskutieren
Orphan drug market support blockbuster potential for OMS721
The company's pipeline is progressing very well and it has released
positive results for three separate compounds in mid-stage trials in the
month of October. It has also addressed funding needs. Omeros has also
been reiterated as a Buy by five different analyst firms during the
month after little activity from the analyst community on this name
throughout 2016. Price targets proffered were all at least double the
current price of the stock as well. The overall range was from $19 to $75 a share.
In the thread Trading Omeros Corp.
Die von marge gewählte maximale Laufzeit wurde überschritten